Non-alcoholic Fatty Liver Disease (NAFLD) Market

Market Overview:

The 7 major Non-alcoholic fatty liver disease (NAFLD) markets reached a value of US$ 13.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.2% during 2024-2034.

The Non-alcoholic fatty liver disease (NAFLD) market has been comprehensively analyzed in IMARC’s new report titled “Non-alcoholic fatty liver disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast”. Non-alcoholic fatty liver disease refers to a medical ailment that is distinguished by an excess of fat deposited in liver cells. This disease can be primarily categorized into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Indiviuals suffering with non-alcoholic fatty liver disease can develop non-alcoholic steatohepatitis, which may further lead to severe scarring (cirrhosis) and liver failure. Non-alcoholic fatty liver disease include some of the common symptoms, such as liver malfunction, pain in the upper right side of the abdomen, fluid and swelling in the stomach (ascites) and legs (edema), malaise, weariness, a dull right-upper-quadrant abdominal discomfort, loss of weight, etc. In some cases, where non-alcoholic fatty liver disease shows no symptoms, it seldom comes to medical attention until tests are performed for other reasons that indicate a liver condition. As a result, this indication necessitates a specific sort of test to be diagnosed. A liver ultrasound scan or magnetic resonance imaging (MRI) can be used to identify metabolic derangements. A liver biopsy is then performed to aid in the diagnosis and differentiation of both kinds of NAFLD (including NAFL and NASH) from other types of liver disease. These specific diagnostics are followed by blood tests, which also contribute to validating the diagnosis.

The increasing prevalence of diabetes and obesity owing to the changing dietary patterns and sedentary lifestyles of the consumers is primarily driving the global non-alcoholic fatty liver disease market. In addition to this, the sudden outbreak of the coronavirus infection has also led to a high risk of hepatic damage and liver-related fatalities, particularly among cirrhotic individuals. This, in turn, is further acting as a significant growth-inducing factor. Moreover, several technological advancements related to genetic testing for early and effective disease diagnosis are also propelling the market growth. Multiple gene mutations are associated with the development of both forms of non-alcoholic fatty liver disease, including NAFL and NASH. Apart from this, the governing agencies of numerous countries, along with non-governmental organizations (NGOs), are supporting various health education campaigns to generate awareness about the risk factors of liver-related disorders, such as non-alcoholic fatty liver disease. Additionally, the introduction of innovative imaging modalities for assessing fatty liver and fibrosis, such as magnetic resonance imaging derived proton density fat fraction and MR elastography, is expected to drive the global non-alcoholic fatty liver disease market in the coming years.

IMARC Group’s new report " Non-alcoholic fatty liver disease (NAFLD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast" provides an exhaustive analysis of the Non-alcoholic fatty liver disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The report provides an in-depth understanding of current and future landscape of the Non-alcoholic fatty liver disease market. This includes treatment practices, in-market and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Non-alcoholic fatty liver disease across the seven major markets. According to the report the United States has the largest patient pool for Non-alcoholic fatty liver disease and also represents the largest market for Non-alcoholic fatty liver disease treatment. Furthermore, the current Non-alcoholic fatty liver disease treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Non-alcoholic fatty liver disease market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, Current and Future Epidemiology Scenario
• Historical, Current and Future Performance of the Non-alcoholic fatty liver disease market
• Historical, Current and Future Performance of Various Therapeutic Categories in the Non-alcoholic fatty liver disease market
• Sales of Various Drugs Across the Non-alcoholic fatty liver disease market
• Reimbursement Scenario in the Non-alcoholic fatty liver disease market
• In-Market and Pipeline Drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Non-alcoholic fatty liver disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Non-alcoholic fatty liver disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to be in 2034?
• What was the country-wise size of the Non-alcoholic fatty liver disease market across the seven major markets in 2023 and how will it look like in 2034?
• What is the growth rate of the Non-alcoholic fatty liver disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the Non-alcoholic fatty liver disease market?
   

Epidemiology Insights

• What is the size of the Non-alcoholic fatty liver disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) of Non-alcoholic fatty liver disease across the seven major markets?
• What are the key factors driving the epidemiological trend of Graft-vs Host Disease?
• What will be the growth rate of Non-alcoholic fatty liver disease patients across the seven major markets?
   

Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed Non-alcoholic fatty liver disease drugs and what are their market performance?
• What are the key pipeline Non-alcoholic fatty liver disease drugs and how are they expected to perform in the coming years?
• How safe are the current marketed Non-alcoholic fatty liver disease drugs and what are their efficacies?
• How safe are the late-stage pipeline Non-alcoholic fatty liver disease drugs and what are their efficacies?
• What are the current treatment guidelines for Non-alcoholic fatty liver disease drugs across the seven major markets?
• Who are the key companies in the Non-alcoholic fatty liver disease market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Non-alcoholic fatty liver disease market?